ARS Pharmaceuticals, Inc. stock is up 54.81% since 30 days ago. The next earnings date is Aug 29, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 3 December’s closed higher than November. In the last 3 Unusual Options Trades, there were 2 CALLs, 1 PUT. 100% of analysts rate it a buy.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.